Company intelligence / Profile preview
Aspeya
Lausanne, Vaud, Switzerlandaspeya.com ↗
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Aspeya has multiple wellness and healthcare products in the market across cannabinoids, inhaled therapeutics, nicotine replacement therapy, and consumer health, leveraging Fertin Pharma’s oral and intra-oral delivery technology, but specific clinical trial results are not publicly disclosed.
- Therapeutic areas
- OtherNeurologyPsychiatry
- Modalities
- Small moleculeBiologicOral drug deliveryInhaled therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Philip Morris International (ownership/collaboration)Fertin Pharma (internal, as CDMO subsidiary)
Beyond the preview
Go deeper on Aspeya.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspeya.